论文部分内容阅读
目的:观察盐酸小檗碱对糖尿病合并系统性白念珠菌感染大鼠的降糖、抗真菌作用。方法:选用60只雄性SD大鼠,模型组通过尾静脉一次性注射四氧嘧啶建立糖尿病模型成功后,再一次性注射白念珠菌,随机分为6组:正常组,模型组,FCZ组,BBR大(300mg.kg-1.d-1)、小剂量组(150mg.kg-1.d-1),BBR联合FCZ组。治疗干预2周后监测空腹血糖、血清TNF-α、肝肾真菌菌落形成单位(CFU)及组织病理PAS染色的变化。结果:大、小剂量BBR与联合治疗组均明显降低空腹血糖、血清TNF-α,与模型组有明显差异(P<0.05),大剂量BBR组与FCZ组的抗真菌作用最强。模型组肝脏出现肝细胞小泡性脂肪变,肾脏出现肾小球体积增大,肾小管上皮细胞空泡变性,并见炎症细胞浸润及大量菌丝和孢子。大剂量BBR组的肝脏、肾脏略黄染,但形态学基本正常,无菌丝与孢子。小剂量BBR与联合组的肝肾组织病理学改变明显比模型组改善。结论:盐酸小檗碱能降低血糖,血清TNF-α浓度,抗白念珠菌,呈剂量依赖性,对糖尿病合并系统性白念珠菌感染有治疗作用。
Objective: To observe the hypoglycemic and antifungal effects of berberine hydrochloride in diabetic rats infected with Candida albicans. Methods: Sixty male Sprague-Dawley rats were randomly divided into 6 groups: normal group, model group, FCZ group, model group, model group, model group, alloxan-induced diabetes mellitus group, BBR (300mg.kg-1.d-1), low-dose group (150mg.kg-1.d-1), BBR combined with FCZ group. The changes of fasting blood glucose, serum TNF-α, colony-forming unit of liver and kidney fungus (CFU) and histopathological PAS staining were monitored 2 weeks after treatment intervention. Results: Compared with the model group, the fasting blood glucose and the serum level of TNF-α in large and small dose of BBR and the combination therapy group were significantly decreased (P <0.05). The antifungal effect of high dose BBR group and FCZ group was the strongest. In the model group, hepatocyte vesicle steatosis appeared in the liver, glomerulus volume increased in the kidney, vacuolar degeneration in renal tubular epithelial cells, infiltration of inflammatory cells and a large number of mycelium and spores. In the BBR group, the liver and kidney were slightly yellowish, but the morphology was basically normal without hyphae and spores. The pathological changes of liver and kidney in low-dose BBR and combination group were significantly improved compared with model group. Conclusion: Berberine hydrochloride can reduce blood glucose, serum TNF-α concentration, anti-Candida albicans in a dose-dependent manner, and has a therapeutic effect on diabetic patients with systemic Candida albicans infection.